Santosh Gautam, PhD

Associate Director
Johnson & Johnson

Poster(s):

• (PA-414) Cost per Responder Model of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) for Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma
  Wednesday, September 17, 2025